Abivax is strengthening its sales team to prepare for the market launch of obefazimod

Abivax, a biotechnology company specializing in therapies for chronic inflammatory diseases, has announced four strategic appointments to key positions within its commercial leadership team. These hires are aimed at preparing for the commercial launch of obefazimod in the United States, with a marketing authorization application expected in the fourth quarter of 2026.

Michael Nesrallah, Chief Commercial Officer, emphasizes the importance of these appointments in strengthening the company's expertise in commercial strategies for chronic inflammatory diseases. The new team members, with backgrounds in renowned companies, will bring valuable expertise to the potential launch of this innovative drug.